BIOMARKER:

FLT3 mutation

News alerts, weekly reports and conference planners

Entrez ID:

2322

Related biomarkers:

‹

›

FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: A1 - Approval SOHO 2022 - 1 week (New C3) gilteritinib Sensitive : A1 SOHO 2022 - 1wk	gilteritinib Sensitive: A1 - Approval SOHO 2022 - 1 week gilteritinib Sensitive : A1 SOHO 2022 - 1 week - (New C3)
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: A2 - Guideline SOHO 2022 - 1 week (New C3) venetoclax Sensitive : A2 SOHO 2022 - 1wk	venetoclax Sensitive: A2 - Guideline SOHO 2022 - 1 week venetoclax Sensitive : A2 SOHO 2022 - 1 week - (New C3)
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: A1 - Approval midostaurin Sensitive : A1	midostaurin Sensitive: A1 - Approval midostaurin Sensitive : A1
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	FLT3 inhibitor Sensitive: B - Late Trials FLT3 inhibitor Sensitive : B	FLT3 inhibitor Sensitive: B - Late Trials FLT3 inhibitor Sensitive : B
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	venetoclax + azacitidine Sensitive: B - Late Trials venetoclax + azacitidine Sensitive : B	venetoclax + azacitidine Sensitive: B - Late Trials venetoclax + azacitidine Sensitive : B
FLT3 mutation	Leukemia	FLT3 mutation	Leukemia	midostaurin Sensitive: B - Late Trials midostaurin Sensitive : B	midostaurin Sensitive: B - Late Trials midostaurin Sensitive : B
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	HM43239 Sensitive: B - Late Trials HM43239 Sensitive : B	HM43239 Sensitive: B - Late Trials HM43239 Sensitive : B
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	sunitinib Sensitive: C2 – Inclusion Criteria sunitinib Sensitive : C2	sunitinib Sensitive: C2 – Inclusion Criteria sunitinib Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	Hypomethylating agent + venetoclax Sensitive: C2 – Inclusion Criteria Hypomethylating agent + venetoclax Sensitive : C2	Hypomethylating agent + venetoclax Sensitive: C2 – Inclusion Criteria Hypomethylating agent + venetoclax Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	CEP-701 Sensitive: C2 – Inclusion Criteria CEP-701 Sensitive : C2	CEP-701 Sensitive: C2 – Inclusion Criteria CEP-701 Sensitive : C2
FLT3 mutation	Myelodysplastic Syndrome	FLT3 mutation	Myelodysplastic Syndrome	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	sorafenib Sensitive: C2 – Inclusion Criteria sorafenib Sensitive : C2	sorafenib Sensitive: C2 – Inclusion Criteria sorafenib Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	FLT3 inhibitor + gilteritinib Sensitive: C2 – Inclusion Criteria FLT3 inhibitor + gilteritinib Sensitive : C2	FLT3 inhibitor + gilteritinib Sensitive: C2 – Inclusion Criteria FLT3 inhibitor + gilteritinib Sensitive : C2
FLT3 mutation	Myelodysplastic Syndrome	FLT3 mutation	Myelodysplastic Syndrome	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	venetoclax + midostaurin Sensitive: C3 – Early Trials venetoclax + midostaurin Sensitive : C3	venetoclax + midostaurin Sensitive: C3 – Early Trials venetoclax + midostaurin Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	venetoclax + gilteritinib Sensitive: C3 – Early Trials venetoclax + gilteritinib Sensitive : C3	venetoclax + gilteritinib Sensitive: C3 – Early Trials venetoclax + gilteritinib Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	venetoclax + sorafenib Sensitive: C3 – Early Trials venetoclax + sorafenib Sensitive : C3	venetoclax + sorafenib Sensitive: C3 – Early Trials venetoclax + sorafenib Sensitive : C3
FLT3 mutation	Non Small Cell Lung Cancer	FLT3 mutation	Non Small Cell Lung Cancer	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	cytarabine + clofarabine Sensitive: C3 – Early Trials cytarabine + clofarabine Sensitive : C3	cytarabine + clofarabine Sensitive: C3 – Early Trials cytarabine + clofarabine Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	cytarabine + cladribine Sensitive: C3 – Early Trials cytarabine + cladribine Sensitive : C3	cytarabine + cladribine Sensitive: C3 – Early Trials cytarabine + cladribine Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	FLT3 inhibitor + venetoclax + decitabine Sensitive: C3 – Early Trials FLT3 inhibitor + venetoclax + decitabine Sensitive : C3	FLT3 inhibitor + venetoclax + decitabine Sensitive: C3 – Early Trials FLT3 inhibitor + venetoclax + decitabine Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials midostaurin + gemtuzumab ozogamicin Sensitive : C3	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials midostaurin + gemtuzumab ozogamicin Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	CA-4948 Sensitive: C3 – Early Trials CA-4948 Sensitive : C3	CA-4948 Sensitive: C3 – Early Trials CA-4948 Sensitive : C3
FLT3 mutation	Myelodysplastic Syndrome	FLT3 mutation	Myelodysplastic Syndrome	CA-4948 Sensitive: C3 – Early Trials CA-4948 Sensitive : C3	CA-4948 Sensitive: C3 – Early Trials CA-4948 Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	midostaurin + cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials midostaurin + cytarabine / daunorubicin liposomal formulation Sensitive : C3	midostaurin + cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials midostaurin + cytarabine / daunorubicin liposomal formulation Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C4 – Case Studies cytarabine / daunorubicin liposomal formulation Sensitive : C4	cytarabine/daunorubicin liposomal formulation Sensitive: C4 – Case Studies cytarabine / daunorubicin liposomal formulation Sensitive : C4

FLT3 mutation

Associations